Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).

Published

Journal Article

OBJECTIVE: Cognitive impairment, manifested as mild to moderate deviations from psychometric norms, is present in many but not all schizophrenia patients. The purpose of the present study was to compare the effect of haloperidol with that of second-generation antipsychotic drugs on the cognitive performance of patients with schizophreniform disorder or first-episode schizophrenia. METHODS: Subjects were 498 patients with schizophreniform disorder or first-episode schizophrenia who were randomly assigned to open-label haloperidol (1 to 4 mg/day [N=103]), amisulpride (200 to 800 mg/day [N=104]), olanzapine (5 to 20 mg/day [N=105]), quetiapine (200 to 750 mg/day [N=104]), or ziprasidone (40 to 160 mg/day [N=82]). The Rey Auditory Verbal Learning Test, Trail Making Test Part A and Part B, WAIS Digit Symbol Test, and Purdue Pegboard Test were administered at baseline and the 6-month follow-up evaluation. RESULTS: Compared with scores at baseline, composite cognitive test scores improved for all five treatment groups at the 6-month follow-up evaluation. However, there were no overall differences among the treatment groups. In addition, there was a weak correlation between the degree of cognitive improvement and changes in Positive and Negative Syndrome Scale scores. CONCLUSION: Treatment with antipsychotic medication is associated with moderate improvement in the cognitive test performance of patients who have schizophreniform disorder or who are in their first episode of schizophrenia. The magnitude of improvement does not differ between treatment with haloperidol and treatment with second-generation antipsychotics. Moreover, cognitive improvement is weakly related to symptom change.

Full Text

Duke Authors

Cited Authors

  • Davidson, M; Galderisi, S; Weiser, M; Werbeloff, N; Fleischhacker, WW; Keefe, RS; Boter, H; Keet, IPM; Prelipceanu, D; Rybakowski, JK; Libiger, J; Hummer, M; Dollfus, S; López-Ibor, JJ; Hranov, LG; Gaebel, W; Peuskens, J; Lindefors, N; Riecher-Rössler, A; Kahn, RS

Published Date

  • June 2009

Published In

Volume / Issue

  • 166 / 6

Start / End Page

  • 675 - 682

PubMed ID

  • 19369319

Pubmed Central ID

  • 19369319

Electronic International Standard Serial Number (EISSN)

  • 1535-7228

Digital Object Identifier (DOI)

  • 10.1176/appi.ajp.2008.08060806

Language

  • eng

Conference Location

  • United States